J&J, Amarin cardiovascular drugs are cost-effective, ICER says—but there's a catch
admin 17th October 2019 Uncategorised 0Both Johnson & Johnson and Amarin scored preliminary wins in July when two of their cardiovascular drugs were deemed cost-effective by an influential U.S. price watchdog. A follow-up report released Thursday backs up those findings—but there’s a catch.
More: J&J, Amarin cardiovascular drugs are cost-effective, ICER says—but there's a catch
Source: fierce